Biovitrum, Syntonix Begin Trial With Hemophilia Treatment
Swedish drugmaker Biovitrum and its U.S. partner Syntonix have obtained permission from the FDA to begin a Phase I/II trial of IV recombinant Factor IX (FIXFc) for patients with hemophilia B.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.